穿皮冠状动脉干预后立即使用无阿司匹林P2Y12抑制剂单疗法:系统性审查
Shenglong Yu1, Linjuan Guo2, Huizhuang Guo3
1Department of Cardiovascular, the Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, China.
Heliyon
|August 22, 2024
概括
通过皮肤冠状动脉干预 (PCI) 后的无阿司匹林P2Y12抑制剂单疗法显示有望减少出血. 然而,与标准的双重抗血小板治疗 (DAPT) 相比,需要进一步的研究来确认其安全性和有效性.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学 是一个学科.
背景情况:
- 穿皮冠状动脉干预 (PCI) 后的双重抗血小板疗法 (DAPT) 是标准的,但与出血风险相关.
- 减少DAPT持续时间并转向P2Y12抑制剂单疗是缓解出血事件的潜在策略.
- 在PCI后立即使用无阿司匹林的P2Y12抑制剂单疗法需要进一步研究其安全性和有效性.
研究的目的:
- 系统地审查评估P2Y12抑制剂单一治疗没有PCI后初始DAPT的研究.
- 在接受PCI的患者中评估无阿司匹林P2Y12抑制剂单疗法的安全性和有效性.
主要方法:
- 在PubMed和Embase数据库中进行系统的文献搜索,截至2024年1月.
- 包括四个单臂试点前性研究和一个随机对照试验 (STOPDAPT-3).
- 分析不同患者队伍的缺血和出血终点率,并与标准DAPT进行比较.
主要成果:
- 单臂研究表明,在急性冠状动脉综合征患者中,缺血 (2.91%) 和出血 (1.09%) 事件的发生率较低,在P2Y12单疗法后的阿司匹林戒断后.
- 在稳定的冠状动脉疾病患者中,缺血和出血终点的发病率非常低 (0.25%).
- 在STOPDAPT-3试验中,在无阿司匹林的普拉苏格勒单一疗法和标准的DAPT之间,在初级缺血或出血终点上没有发现显著差异,但在无阿司匹林的方法中,注意到冠状动脉再血管化和支架血栓形成的风险增加.
结论:
- 在PCI后立即开始的无阿司匹林P2Y12抑制剂单疗法在选择的ACS和稳定的CAD患者中似乎是安全的和可行的.
- 需要进一步的研究,以确定该策略与标准DAPT相比的安全性和有效性.
- 潜在的权衡,包括增加复血管化和支架血栓形成风险,需要仔细考虑.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
501
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
501
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
464
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464
01:26Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149